Influenza A virus-treated human platelets were lyzed in autologous serum. Lysis required the presence of antibody and occurred predominantly through activation of the classical complement pathway. Binding of the virus followed by its elution at 37 degrees C resulted in a dose-dependent desialation of the cells with a maximal release of 45% of total platelet sialic acid. In contrast, platelets that had been treated with Vibrio cholerae neuraminidase and from which 55% of total sialic acid had been removed were not lyzed in autologous serum and did not bind C3 as shown in binding assays using radiolabeled monoclonal anti-C3 antibody. Thus, the immune-mediated lysis of virus-treated platelets in autologous serum did not involve neoantigens expressed by desialated cells. To assess the effect of viruses on the platelet surface, treated platelets were incubated with galactose oxidase and sodium [3H]borohydride prior to separation and analysis of the labeled glycoproteins by SDS-PAGE. Viral treatment resulted in a desialation of each of the surface glycoproteins. At the same time, a labeled component of Mr 72,000 (nonreduced) and Mr 55,000 (reduced) was observed that was not present when V. cholerae-desialated platelets were examined in the same way. Immunoblotting experiments performed using antiwhole virus and antihemagglutinin antibodies demonstrated this component to be viral hemagglutinin. As bstract. Influenza A virus-treated human platelets were lyzed in autologous serum. Lysis required the presence of antibody and occurred predominantly through activation of the classical complement pathway. Binding of the virus followed by its elution at 370C resulted in a dose-dependent desialation of the cells with a maximal release of 45% of total platelet sialic acid. In contrast, platelets that had been treated with Vibrio cholerae neuraminidase and from which 55% of total sialic acid had been removed were not lyzed in autologous serum and did not bind C3 as shown in binding assays using radiolabeled monoclonal anti-C3 antibody. Thus, the immune-mediated lysis of virus-treated platelets in autologous serum did not involve neoantigens expressed by desialated cells. To assess the effect of viruses on the platelet surface, treated platelets were incubated with galactose oxidase and sodium [3H]borohydride prior to separation and analysis of the labeled glycoproteins by SDS-PAGE. Viral treatment resulted in a desialation of each of the surface glycoproteins. At the same time, a labeled component of M, 72,000 (nonreduced) and M, 55,000 (reduced) was observed that was not present when V. cholerae-desialated platelets were examined in the same way. Immunoblotting experiments performed using antiwhole virus and anti-hemagglutinin antibodies demonstrated this component to be viral hemagglutinin. Involvement of membrane-bound hemagglutinin in antibody and in complement-mediated lysis of virus-treated platelets in autologous serum was
As bstract. Influenza A virus-treated human platelets were lyzed in autologous serum. Lysis required the presence of antibody and occurred predominantly through activation of the classical complement pathway. Binding of the virus followed by its elution at 370C resulted in a dose-dependent desialation of the cells with a maximal release of 45% of total platelet sialic acid. In contrast, platelets that had been treated with Vibrio cholerae neuraminidase and from which 55% of total sialic acid had been removed were not lyzed in autologous serum and did not bind C3 as shown in binding assays using radiolabeled monoclonal anti-C3 antibody. Thus, the immune-mediated lysis of virus-treated platelets in autologous serum did not involve neoantigens expressed by desialated cells. To assess the effect of viruses on the platelet surface, treated platelets were incubated with galactose oxidase and sodium [3H]borohydride prior to separation and analysis of the labeled glycoproteins by SDS-PAGE. Viral treatment resulted in a desialation of each of the surface glycoproteins. At the same time, a labeled component of M, 72,000 (nonreduced) and M, 55 ,000 (reduced) was observed that was not present when V. cholerae-desialated platelets were examined in the same way. Immunoblotting experiments performed using antiwhole virus and anti-hemagglutinin antibodies demonstrated this component to be viral hemagglutinin. Involvement of membrane-bound hemagglutinin in antibody and in complement-mediated lysis of virus-treated platelets in autologous serum was supported by the Introduction Thrombocytopenia may accompany or follow the onset of a variety of viral diseases. These include infections with ortho and paramyxoviruses, such as influenza (1, 2) , Newcastle (3), measles (4), or rubella (5) and other viruses such as chicken pox (6) , Dengue (7) , and cytomegalovirus (8) . Thrombocytopenia, which may be associated with a shortened survival of platelets after transfusion (9) , usually occurs after maximal viremia, at a time when a specific immune response has developed. Thus, accelerated clearance of platelets could follow adsorption of immune complexes to platelet Fc receptors; alternatively, antibodies could interact with neoantigens expressed on altered platelet membranes after their contact with virus or with platelet-associated viral antigens in a mechanism analogous to that recently demonstrated for immune-mediated thrombocytopenias in malarial infections (10) .
Influenza viruses bind to specific receptors on cell membranes and elute from the cells through cleavage of N-acetyl neuraminic acid residues by viral neuraminidase (1 1, 12) . The accelerated clearance of platelets in vivo following their interaction with influenza virus in vitro has been related to virusinduced desialation of the cells (1, 3, 13) . As it has been suggested for erythrocytes (14) , thrombocytopenia in this model could result from the binding ofdesialated platelets to galactose receptors on cells of the reticulo-endothelial system; other mechanisms for enhanced clearance of desialated cells could involve C3b deposition following activation of the alternative complement pathway (15, 16) and/or lysis following antibodydependent activation of the classical pathway (17, 18) . In the present study, we provide evidence to show that incubation of human platelets with suspensions of influenza virus, but not with bacterial neuraminidase, results in complement and antibody-mediated lysis of platelets in autologous serum. The crucial event was the interaction of immunoglobulins with viral hemagglutinin present on the platelet membrane. Such a mechanism could provide a major pathway for platelet clearance in viral infections at the time of the specific immune response or in hosts that had been preimmunized with crossreactive viral antigens.
Methods
Buffers. Veronal-buffered saline (VBS)', VBS containing 0.15 mM calcium and 0.5 mM magnesium (VBS++), VBS containing 0.04 M EDTA (VBS-EDTA), VBS containing 2 mM magnesium and 8 mM EGTA (VBS-Mg EGTA), VBS containing 0.1% gelatin (GVB), GVB containing 2 mM magnesium and 8 mM EGTA (GVB-Mg EGTA) and GVB containing 0.04 M EDTA (GVB-EDTA), were prepared as described (19, 20) .
Washed platelets. In a typical experiment, blood (100 ml) was collected from a healthy adult donor into two 50 ml tubes each containing 7.5 ml acid-citrate-dextrose anticoagulant (National Institutes of Health formula A) and 50 units of heparin (Choay, Paris, France). Platelet-rich plasma was prepared by centrifugation at 120 g for 15 min at 30'C. The platelets were sedimented by centrifugation at 1,000 g for 15 min at 30'C, resuspended in 10 ml of Tyrode's buffer, pH 7.4, containing 0.35% wt/vol bovine serum albumin (BSA; Tyrodealbumin), apyrase (purified, 0.03 ,g/ml, kindly provided by Dr. J.-P.
Cazenave, Strasbourg, France) and 100 units of heparin, and incubated in this buffer for 10 min at 37°C. After addition of prostacyclin (PGI2) (10-' M), the platelets were sedimented at 700 g for 6 min at 30°C. The platelets were resuspended and washed once more as above except for the fact that heparin was omitted from the buffer. Finally, the platelets were resuspended in Tyrode-albumin buffer containing apyrase and used within 4 For viral treatment of platelets, I X 109 washed platelets were incubated with purified influenza virus (800-20,000 HAU) in 5 ml Tyrode-albumin buffer containing apyrase for 15 min at 40C. Incubation was performed at low temperature to allow the viruses to bind to the cell membrane without inducing platelet agglutination or granule release. When platelets were washed after their incubation with virus, no hemagglutinating activity could be detected in the supernatant, indicating that in the experimental conditions that were used, all viral particles became bound to the platelets at 40C. The platelet suspensions were then incubated in Tyrode-albumin buffer containing apyrase for 60 min at 370C to allow neuraminidase activity and viral elution. The platelets were sedimented by centrifugation at 700 g for 5 min at 30'C and washed once prior to their resuspension and incubation for another 60 min at 37°C in the same buffer. Viral particles were effectively eluted from the treated platelets during the incubations at 37°C since all the virus was recovered as hemagglutinating activity in the washes and since no residual viral particles were seen on examination of the surface of treated platelets by scanning electron microscopy ( Fig. 1) . Conventional transmission electron microscopy of 2.5% glutaraldehydefixed platelets demonstrated that treated platelets were disc-shaped with a normal granule content. In some cases, one or two ingested viral particles were seen in vesicles in intact cells. Virus-treated platelets were used immediately. Control platelets were prepared under the same conditions but in the absence of virus.
Treatment of platelets with Vibrio cholerae neuraminidase. For treatment with bacterial neuraminidase, 6 X 10 washed platelets in 1.0 ml of 0.05 M Na acetate, 0.135 M NaCI, 4 mM CaC12, pH 6.5, were incubated for 45 min at 37°C with an equal volume of buffer containing 0.04-1.0 IU of V. cholerae neuraminidase (<0.0002 um/ mg protease; Boehringwerke AG, Marburg-lahn, West Germany). The treated platelets were sedimented at 700g for 5 min at 30°C and resuspended in Tyrode-albumin buffer. For determination of sialic acid associated with membranes of untreated platelets, platelets that had been treated with viral particles, or those treated with bacterial neuraminidase, 6 X 108 cells were hydrolyzed in 0.1 N H2SO4 at 80°C for 60 min and free sialic acid was assayed by the thiobarbituric acid method (23) .
Serum. Serum was obtained from the platelet donors and used immediately or stored at -70°C. For one donor, serum was obtained before and after immunization with influenza vaccine (Mutagrip, Institut Pasteur, Paris). Postvaccinal serum from this donor was absorbed with purified virus (21) by incubating 1.0 ml of serum with an equal volume of VBS++ containing 150,000 HAU for 4 h at 2°C. Virus particles were pelleted by centrifugation at 65,000 g for 12 h at 4°C. Serum from a child with primary agammaglobulinemia was obtained before and after treatment with gammaglobulins and was a kind gift from Dr. A. Fischer (H6pital des Enfants Malades, Paris). The total complement hemolytic activity (CH50) of the serum before and after treatment was normal. Anti-hemagglutinin antibodies in serum were measured using an inhibition of hemagglutination test (HAI) (I 1).
Anti-viral antibodies. Viral hemagglutinin (HA) was purified from influenza A virus 3QB (H3N2) Hong Kong variant after treating the purified virus with bromelain as described (24, 25) . Anti-whole virus antibodies were obtained in rabbits (21). Anti-HA antibodies were obtained first by injecting 100 Mg of purified HA in complete Freund's adjuvant into the footpads of a Fauve de Bourgogne rabbit and by boosting the animal after I and 3 wk with 200 Mg of protein in CFA injected intramuscularly and after 6 wk by injecting intravenously 100 Mig of antigen. The rabbit was bled 5 d after the last injection. The titer of anti-viral and anti-HA antibodies in sera from immunized animals was determined using HAI and an enzyme-linked immunosorbent assay (21).
Complement assays. CH50 (26), C3 (27) , and B (28) serum hemolytic activities were measured as described. C2 hemolytic activity was assessed using cellular intermediates bearing guinea pig Cl and human C4 (29) . C3 uptake studies. In vitro C3 uptake onto platelets was quantitated using mouse monoclonal anti-human C3 IgG antibody that had been purified from ascitic fluid (Bethesda Research Laboratories, Gaithersburg, Md.) by affinity chromatography on protein A sepharose (Pharmacia Fine Chemicals, Piscataway, NJ). The antibody was radiolabeled with "2I (Amersham Corp.) to a specific activity of 350,000 cpm/Mug by means of Iodo-Gen (Pierce Chemical Co., Rockford, IL) according to the manufacturer's instructions. Aliquots of 109 platelets were incubated in 1 ml of a 1:3 dilution of autologous serum in VBS+, GVB-Mg EGTA, or GVB-EDTA2 for 60 min at 37°C. After addition 2. Dilution of the serum in VBS++ allows complement activation by both the classical and the alternative complement pathways. Dilution in Mg EGTA excludes classical pathway activation. of 3 ml of ice-cold GVB-EDTA, the platelets were pelleted, washed once in GVB-EDTA, and incubated in 0.3 ml of the same buffer containing radiolabeled antibody (900,000 cpm) for 30 min at 30'C. Duplicate 75 ul samples of the reaction mixture were then centrifuged through a mixture of oil for I min at 8,000 g (30) . The tubes were cut and radioactivity associated with the platelets was determined in an LKB 1275 gamma counter (LKB Instruments, Inc.). Specific C3 deposition on platelets was calculated by first substracting the number of '25l-labeled monoclonal anti-C3 antibody molecules that bound to untreated and to neuraminidase or virus-treated platelets incubated in serum diluted in GVB-EDTA from that bound to platelets incubated in serum diluted in VBS++ or GVB-Mg EGTA2. These values were then used in substracting the number of antibody molecules bound to untreated platelets from that which bound to treated platelets.
Surface labeling and analysis of platelet glycoproteins by SDSpolyacrylamide gel electrophoresis (PAGE). Washed suspensions of platelets at I X 109/ml were either incubated with purified virus (20,000 HAU) as described in the previous section or V. cholerae neuraminidase (I IU/ml) during 1 h at 370C. Appropriate controls were performed in the absence of added virus particles or V. cholerae neuraminidase. 3H-labeling of the surface glycoproteins oftreated platelets was performed according to the procedure of Nurden et al. (31) . In brief, suspensions of 109 platelets in I ml phosphate-buffered saline (PBS), pH 7.4, were first incubated with 10 U/ml of galactose oxidase (Kabi Diagnostics, Stockholm, Sweden) for 5 min at 37°C. After sedimentation and resuspension in I ml PBS, the platelets were incubated with 0.5 mCi sodium [3H]borohydride (16 Ci/mmol; Commissariat a l'Energie Atomique, Saclay, France) for 15 min at room temperature. After washing, the 3H-labeled platelets were resuspended at 2 X I09 platelets/ml in Tris-HCI, 0.15 M NaCl, 3 mM EDTA, pH 7.0, and solubilized by heating at 1000C for 5 min in the presence of 2% (wt/vol) SDS and 5 mM N-ethylmaleimide. When performed, disulfides were reduced by incubating SDS-solubilized samples at 370C for I h in the presence of 5% 2-mercaptoethanol. All materials for SDS-PAGE were of electrophoresis purity grade and were obtained from Bio-Rad Laboratories (Richmond, CA). These included the high and low molecular weight standards used for molecular weight determination by SDS-PAGE. Samples (100 ug protein) were analyzed by electrophoresis on 7-12% gradient acrylamide slab gels (31, 32) . Proteins were detected by Coomassie blue staining and 3H-labeled glycoproteins by fluorography using EN3HANCE (New England Nuclear, Boston, MA) (31). The gels were dried onto filter paper and exposed to Kodak X-Omat MA film (Kodak-Pathe, Paris, France) for up to 3 wk at -70'C.
Identifcation ofplatelet-bound virus antigens using Western blots.
Virus-treated platelets were prepared as described above and solubilized directly with SDS without prior 3H-labeling. Samples (50 Ag protein)
were electrophoresed with and without disulfide reduction on 7-12% gradient acrylamide slab gels. A small aliquot (10 ul) of a 0.05 mg/ml solution of pyronin Y was added to each sample to act as a marker for the front migration after the electrophoresis. Transfer of the separated polypeptides to nitrocellulose membranes (Bio-Rad Laboratories) was performed according to the method of Towbin et al. (Fig. 3) .
Significantly, incubation in autologous serum diluted in VBS"õ f platelets from which 50% of the membrane-associated sialic acid had been removed using V. cholerae neuraminidase did not result in lysis of the cells nor in complement consumption. The number of C3 molecules that specifically bound to V. cholerae neuraminidase-treated platelets following their incubation in autologous serum diluted in VBS"~or in GVB-Mg EGTA was quantitated and compared with that which bound to virus-treated platelets under the same experimental conditions. No C3 specifically bound to neuraminidase-treated platelets, whereas 5,000 and 1,600 C3 molecules (per platelet) bound to p1-v following their incubation for 60 mmn in autologous serum diluted in VBS" and Mg EGTA, respectively (Fig. 4) . The number of C3 molecules which bound to p1-v membrane than that with desialation, which was responsible for antibody-dependent lysis of pl-v in autologous serum.
Virus-induced modifications ofthe platelet surface. Platelets incubated with viruses or V. cholerae neuraminidase were treated with galactose oxidase and sodium [3Hlborohydride.
The 3H-labeled glycoproteins were separated and analyzed by SDS-PAGE. Coomassie blue staining revealed identical polypeptide profiles for the virus and V. cholerae neuraminidasetreated platelets (not illustrated). Fluorography showed extensive 3H-labeling of the major membrane glycoproteins of both platelet preparations (Fig. 5) . Little labeling was observed after control incubations performed in the absence of added virus or bacterial neuraminidase. Thus, it was apparent that incubation of platelets with influenza viruses had resulted in sialic acid removal from each of the major surface glycoproteins. One notable feature of the 3H-labeling patterns was the additional presence of a M, 72,000 band on analysis of nonreduced samples of virus-treated platelets. Following disulfide reduction, this component migrated with a Mr of 55,000. Such a mobility change did not correspond to that of a known platelet membrane glycoprotein, but resembled that of influenza virus hemagglutinin and the HAl subunit of this protein (25, 35) . Blotting experiments were then performed using rabbit antiwhole virus and anti-viral hemagglutinin antisera. The results confirmed that the Mr 72,000 component expressed antigenic determinants of viral hemagglutinin (Fig. 6) . After disulfide reduction, the bulk of the anti-hemagglutinin antibodies were observed to bind to the 55,000 subunit (not illustrated). High molecular weight material (Fig. 6, lanes a and b) revealed by both anti-whole virus and anti-hemagglutinin antibodies on analysis of nonreduced virus-treated platelet proteins was no longer observed after disulfide reduction, suggesting it represented aggregates of hemagglutinin. No specific antibody binding was observed on analysis of V. cholerae neuraminidasetreated platelets and in all cases when using nonimmune rabbit sera. Thus, membranes of virus-treated platelets express antigenic determinants of viral hemagglutinin that remain bound to the platelet membrane after viral treatment of the cells.
Increased lytic activity of a human serum containing an elevated titer of anti-hemagglutinin antibodies. The possibility that lytic antibodies to influenza virus-treated platelets were directed against viral hemagglutinin that was bound to the platelet membrane was then examined by incubating virustreated platelets in autologous serum that was obtained before and 2 wk after inoculation of a healthy donor with influenza vaccine made of inactivated Bangkok H3N2 and Texas HlNl A strains and Singapur B strain. After vaccination, serum HAI antibodies to the H3N2 strain rose from a titer of 1:10 to 1:80. Serum total complement hemolytic activity remained unchanged. In parallel, the lytic capacity of the serum towards virus-treated platelets increased so that 55% of the platelets were lyzed and no residual complement hemolytic activity was found in postvaccinal serum in VBS++ after 130-min incubation, whereas only 19% of pl-v were lyzed and 31% CH50 was consumed in prevaccinal serum under the same conditions. Absorption of postvaccinal serum with influenza A virus removed all HAI antibodies against H3N2 virus without altering the CH50 and suppressed the lytic activity of the serum for virus-treated platelets.
Discussion
The attachment of myxoviruses to the membrane of erythrocytes, leukocytes, and platelets involves a viral hemagglutinin and specific membrane receptors bearing a terminal N-acetyl neuraminic acid group (1 1, 36 (35) . Consistent with our findings is the localization of the bulk of the bound carbohydrate on the HAl chain and the large proportion of galactose and Nacetylgalactosamine residues within its oligosaccharides (37) . The fact that the hemagglutinin was 3H-labeled confirmed its localization on the surface of the virus-treated platelets. Since both anti-whole virus and anti-hemagglutinin antibodies revealed a single major component, our studies suggest that hemagglutinin is the dominant antigen remaining on the treated platelets. The decreased recognition by anti-hemagglutinin antibodies of the Mr 25,000 HA2 subunit of hemagglutinin is not unexpected as previous reports have highlighted the predominant expression of hemagglutinin antigenic determinants by the HAl subunit of HA (37, 38) . Membrane-bound hemagglutinin could represent protein remaining after elution of the virus from the cells, or protein which bound following the interaction of platelets with free hemagglutinin present in the viral suspension.
Involvement of membrane-bound viral protein in antibody and complement-dependent lysis of virus-treated platelets in autologous serum was demonstrated by the increased lysis that resulted from the increase in complement-fixing anti-hemagglutinin antibodies in the test serum following vaccination and by suppression of the lytic activity of the postvaccinal serum for pl-v following adsorption with purified virus. It is possible that among peripheral blood cells, altered platelets represent a privileged target for autologous complement because they are capable of uptake of the terminal complement C5b-9 complex (39) and because they lack the C3b receptor that is a potent inhibitor of complement activation. Accelerated clearance of platelets following their contact with influenza virus (1, 3) , and possibly, clearance of other cells on which influenza A antigen can be demonstrated in vivo during peak infection with influenza (40) could result from both antibody and complement-mediated lysis, and from antibody-dependent C3 deposition that would result in the interaction of the target cell with C3b receptors on cells from the reticuloendothelial system (41) . The prevalence of anti-hemagglutinin antibodies in the normal population is very high. Following infection with influenza virus, interstrain cross-reactive complement fixing anti-hemagglutinin antibodies are the major feature of the ongoing immune response. Binding of a viral protein to integral membrane glycoproteins after contact of human platelets with influenza virus or with viral hemagglutinin provides a model for immune thrombocytopenias occurring during acute viral infections at the time of the specific immune response.
